Clinical Psychopharmacology and Neuroscience indexed in CAS, DOI/Crossref, EMBASE, Korea Citation Index (KCI), KoreaMed, Korea Medical Citation Index (KoMCI), PubMed, PubMed Central (PMC), SCOPUS, SCI-expanded (SCIE), and Google Scholar:eISSN 2093-4327   pISSN 1738-1088

Cited by CrossRef (29)

  1. R Dhivya Karoline, Samuvel Sekar, SS Asha Charitha, Jibi Achamma Jacob. Cariprazine augmentation in a patient with clozapine-resistant schizophrenia. 2023;32:S279
    https://doi.org/10.4103/ipj.ipj_208_23
  2. Borjanka Batinic, Ivan Ristic, Milica Zugic, David S. Baldwin. Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine. Front. Psychiatry 2021;12
    https://doi.org/10.3389/fpsyt.2021.784370
  3. Octavian Vasiliu. Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence?. Front. Psychiatry 2022;13
    https://doi.org/10.3389/fpsyt.2022.1069432
  4. . Antipsychotics. Reactions Weekly 2021;1848:61
    https://doi.org/10.1007/s40278-021-93063-x
  5. Stephan Hjorth. The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective. Front. Psychiatry 2021;12
    https://doi.org/10.3389/fpsyt.2021.760181
  6. Adam Montgomery, Marianna Rogowska, Luiz Dratcu. Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia?. Clin Psychopharmacol Neurosci 2023;21:202
    https://doi.org/10.9758/cpn.2023.21.1.202
  7. Camilla Gesi, Silvia Paletta, Maria Carlotta Palazzo, Bernardo Dell'Osso, Claudio Mencacci, Giancarlo Cerveri. Cariprazine in Three Special Different Areas: A Real-World Experience. NDT 2021;Volume 17:3581
    https://doi.org/10.2147/NDT.S335332
  8. V. V. Stanovaya, Z. T. Guseynova, M. V. Ivanov, E. V. Bigday. The phenomenon of therapeutic resistance in the treatment of schizophrenia: the possibilities of modern diagnostics and methods of anti-resistant effects. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY 2023;57:120
    https://doi.org/10.31363/2313-7053-2023-893
  9. Filipa Viegas, Tiago Ferreira, Cláudia Campos. Using Cariprazine to Ameliorate Negative Symptoms and Metabolic Side Effects of Clozapine and Paliperidone – Clinical Cases. NDT 2022;Volume 18:1145
    https://doi.org/10.2147/NDT.S343747
  10. John Lyne, Francesco Piacenza, Julija Radovic, Brian O'Donoghue. The effectiveness of adjunctive cariprazine for treatment of negative symptoms: A systematic review of randomised controlled trials. Schizophrenia Research 2024;267:213
    https://doi.org/10.1016/j.schres.2024.03.038
  11. Ashish Patel, Arya Patel, Darshini Patel, Krina Patel, Tushar Bambharoliya. Mini Review on Cariprazine: A Promising Antipsychotic Agent. CNSNDDT 2023;22:226
    https://doi.org/10.2174/1871527321666220324121935
  12. Andrea de Bartolomeis, Mariateresa Ciccarelli, Licia Vellucci, Michele Fornaro, Felice Iasevoli, Annarita Barone. Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia. Expert Opinion on Pharmacotherapy 2022;23:2035
    https://doi.org/10.1080/14656566.2022.2145884
  13. Judith Weise, Georg Schomerus, Sven Speerforck. Add-on Cariprazine in Patients with Long-term Clozapine Treatment and Treatment Resistant Schizophrenia: Two Cases of Psychotic Deterioration and Pisa Syndrome. Clin Psychopharmacol Neurosci 2022;20:398
    https://doi.org/10.9758/cpn.2022.20.2.398
  14. Chelsea Boydstun, Sean Lynch, Patrick DiGenova. Cariprazine: an augmentation strategy for treatment-resistant schizophrenia with pro-cognitive and anti-hostility effects. 2023;38:361
    https://doi.org/10.1097/YIC.0000000000000469
  15. Octavian Vasiliu. Opţiuni terapeutice în schizofrenia ultrarezistentă. Intervenţii farmacologice (I). Psihiatru.ro 2023;72:28
    https://doi.org/10.26416/Psih.72.1.2023.7932
  16. Réka Csehi, Zsófia Borbála Dombi, Barbara Sebe, Mária Judit Molnár. Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies. Front. Psychiatry 2022;13
    https://doi.org/10.3389/fpsyt.2022.827744
  17. Bernardo Dell’Osso, Antonello Bellomo, Andreas Pietro Maria Conca, Virginio Salvi, Alberto Siracusano, Carmelo Zaffora, Domenico De Berardis, Massimo Di Giannantonio. Therapeutic Appropriateness of Cariprazine in the Management of Schizophrenia: Experts’ Opinion using a Delphi Approach. CN 2023;21:2206
    https://doi.org/10.2174/1570159X21666230719162023
  18. Peter Falkai, Zsófia B. Dombi, Károly Acsai, Ágota Barabássy, Andrea Schmitt, György Németh. The efficacy and safety of cariprazine in the early and late stage of schizophrenia: a post hoc analysis of three randomized, placebo-controlled trials. CNS Spectr. 2023;28:104
    https://doi.org/10.1017/S1092852921000997
  19. Mats Bogren, Monica Soltesz, Stephan Hjorth. Remission of Persistent Negative Symptoms and Psychosocial Consequences by Combined Clozapine and Cariprazine Treatment in a Patient With Long-Standing Treatment-Resistant Schizoaffective Disorder. Front. Psychiatry 2022;13
    https://doi.org/10.3389/fpsyt.2022.887547
  20. Sofia Pappa, Arturas Kalniunas, Hitendra Sharma, Ali Raza-Syed, Manzar Kamal, Fintan Larkin. Efficacy and safety of cariprazine augmentation in patients treated with clozapine: a pilot study. Therapeutic Advances in Psychopharmacology 2022;12:204512532211320
    https://doi.org/10.1177/20451253221132087
  21. Ebenezer Oloyede, Ivana Clark, Shubhra Mace, Eromona Whiskey, David Taylor. Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review. Therapeutic Advances in Psychopharmacology 2022;12:204512532110666
    https://doi.org/10.1177/20451253211066642
  22. Juan D Duque-Yemail, Juan Carlos Avila. Switching Clozapine to Cariprazine in Three Patients with Persistent Symptoms of Schizophrenia: A Case Series. NDT 2022;Volume 18:1433
    https://doi.org/10.2147/NDT.S367922
  23. Marcin Siwek, Adrian Andrzej Chrobak, Aleksandra Gorostowicz, Patrycja Król, Dominika Dudek. Cariprazine augmentation of clozapine in schizophrenia—a retrospective chart review. Front. Pharmacol. 2024;14
    https://doi.org/10.3389/fphar.2023.1321112
  24. Elmars Rancans, Zsófia Borbála Dombi, Ágota Barabássy. Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia. Front. Psychiatry 2022;12
    https://doi.org/10.3389/fpsyt.2021.770234
  25. Helge HO Müller, Sebastian Moeller. Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases. NDT 2021;Volume 17:1089
    https://doi.org/10.2147/NDT.S303817
  26. Alessandro Serretti. Innovation in psychopharmacology. 2023;38:281
    https://doi.org/10.1097/YIC.0000000000000493
  27. David Taylor, Ramalingam Chithiramohan, Jasdev Grewal, Avirup Gupta, Lars Hansen, Gavin P. Reynolds, Sofia Pappa. Dopamine partial agonists: a discrete class of antipsychotics. International Journal of Psychiatry in Clinical Practice 2023;27:272
    https://doi.org/10.1080/13651501.2022.2151473
  28. Ricardo Coentre, Rodrigo Saraiva, Carolina Sereijo, Pedro Levy. Cariprazine Use in Early Psychosis: Three Case Reports. Front. Psychiatry 2021;12
    https://doi.org/10.3389/fpsyt.2021.788281
  29. Marcin Siwek, Adrian Andrzej Chrobak, Aleksandra Gorostowicz, Patrycja Król, Dominika Dudek. Lurasidone Augmentation of Clozapine in Schizophrenia—Retrospective Chart Review. Brain Sciences 2023;13:445
    https://doi.org/10.3390/brainsci13030445